in 25 days Kaiser Permanente — Kaiser Northwest's Zepbound criteria move to the rev 10/08/2026 document — cite that version in an appeal from this date See the changelog
WalletNoise

Updated as the corpus is

GLP-1 coverage changelog

Every formulary move and price change we track, with the date it takes effect and the document it came from. Scheduled changes first, because those are the ones you can still plan around.

Scheduled — not yet in effect

  1. Kaiser Permanente policy

    Kaiser Northwest's Zepbound criteria move to the rev 10/08/2026 document — cite that version in an appeal from this date

    healthy.kaiserpermanente.org

    in 25 days
  2. Blue Cross Blue Shield Federal Employee Program (FEP) policy

    2027 drug lists published for open season and the weight-loss class carries over unchanged: Zepbound still under DRUGS NOT COVERED on Standard and Basic, Wegovy injection and tablets plus Wegovy HD still Tier 3 with PA, Saxenda Tier 3, generic liraglutide Tier 1, Foundayo still absent

    caremark.com

    in 40 days
  3. Express Scripts (Evernorth / Cigna) policy

    The 2027 National Preferred Formulary keeps the weight-loss class exactly as 2026 left it: Zepbound KwikPens and vials excluded, with liraglutide, Foundayo, Wegovy HD, Wegovy pens, Wegovy tablets and Zepbound pens as the preferred alternatives, and Saxenda excluded in favour of generic liraglutide. Nothing you have to do changes on this date — but cite the 2027 exclusions list, not the 2026 one, in an appeal about a 2027 fill

    express-scripts.com

    in 40 days
  4. LillyDirect self-pay price

    Foundayo™ (orforglipron) 2.5 mg moves from $149 to $199/month. ↑ $50/mo

    foundayo.lilly.com

    in 40 days
  5. LillyDirect self-pay price

    Foundayo™ (orforglipron) 5.5 mg moves from $199 to $299/month. ↑ $100/mo

    foundayo.lilly.com

    in 40 days
  6. Retail list price (reference) price

    Ozempic® (semaglutide) moves from $1,028 to $675/month. ↓ $353/mo

    novonordisk.com

    in 40 days
  7. Retail list price (reference) price

    Wegovy® (semaglutide injection) moves from $1,349 to $675/month. ↓ $674/mo

    novonordisk.com

    in 40 days
  8. Retail list price (reference) price

    Wegovy® tablets (oral semaglutide) moves from $1,349 to $675/month. ↓ $674/mo

    novonordisk.com

    in 40 days

Already in effect

  1. Aetna (CVS Health) policy

    Foundayo moves non-preferred -> preferred, and Zepbound is added to the formulary, both named in Aetna's own Standard Plan formulary update (GR-69746-4) rather than only in the CVS press release

    aetna.com

  2. Aetna (CVS Health) policy

    Zepbound back as additional preferred on templates

    cvshealth.com

  3. CVS Caremark policy

    Zepbound returns to standard commercial template formularies as an additional preferred option

    cvshealth.com

  4. Elevance Health / Anthem (CarelonRx) policy

    Zepbound single-dose pen goes Tier 3 -> non-formulary on the California DMHC National and DMHC Essential lists — the KwikPen took Tier 2 on those same two lists on Aug 1, so DMHC members switch presentation or lose cover; no other Anthem list changes

    anthembluecross.com

  5. Express Scripts (Evernorth / Cigna) policy

    Both NPF documents re-issued with 10/01/2026 revision stamps; the Weight Loss row is unchanged — Zepbound KwikPens and vials stay excluded, with liraglutide, Foundayo, Wegovy HD, Wegovy pens, Wegovy tablets and Zepbound pens as the preferred alternatives. Quote the 10/01/2026 stamp in an appeal, not the 07/01/2026 one

    express-scripts.com

  6. Kaiser Permanente policy

    Wegovy returns to the Kaiser Washington large-group 4-tier formulary at Tier 2 (both Wegovy subcutaneous and Wegovy HD, PA and QL), one tier better than Zepbound

    healthy.kaiserpermanente.org

  7. Medicaid (state-by-state) policy

    Rhode Island Medicaid stops covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, under its enacted FY2027 budget; obesity coverage runs through Sept 30, 2026. Continued treatment for an indication other than weight loss needs a new prior authorization, and requests for members under 21 are reviewed for medical necessity under EPSDT

    eohhs.ri.gov

  8. Optum Rx (UnitedHealthcare) policy

    Weight-loss PA policy P 1114-23 drops the launch-exclusion footnote from Foundayo, hardens the Wegovy tablet footnote to 'typically excluded from coverage', and adds a one-time 6-month reauthorization for patients not yet at a maintenance dose

    uhcprovider.com

  9. LillyDirect self-pay price

    Foundayo™ (orforglipron) 2.5 mg moves from $199 to $149/month. ↓ $50/mo

    foundayo.lilly.com

  10. LillyDirect self-pay price

    Foundayo™ (orforglipron) 5.5 mg moves from $299 to $199/month. ↓ $100/mo

    foundayo.lilly.com

  11. Optum Rx (UnitedHealthcare) policy

    Weight-loss PA policy P 1114-22 adds Foundayo (orforglipron) to the covered drug list at 6 months initial authorization, footnoted as possibly excluded at launch on some plans

    uhcprovider.com

  12. NovoCare Pharmacy self-pay price

    Wegovy® tablets (oral semaglutide) 4 mg moves from $149 to $199/month. ↑ $50/mo

    novocare.com

  13. Medicaid (state-by-state) policy

    BALANCE state application deadline passed; participant list not yet published

    cms.gov

  14. Medicaid (state-by-state) policy

    Indiana announced it would join the BALANCE model, covering GLP-1s for eligible Medicaid members with obesity, on the governor's direction to the Family and Social Services Administration. Reported terms: manufacturers supply the drugs to the state at $245 per member per month, of which Indiana pays $85.16 after the federal match, with a manufacturer-run lifestyle programme at no cost to the state. No eligibility criteria and no start date were published with it, and the agreement was still being finalised. This is the state's own announcement, not a CMS participant listing: no Indiana state document could be retrieved to confirm it, so the terms here rest on the originating local outlet and trade press and should be read as secondary

    indianacapitalchronicle.com

  15. Medicaid (state-by-state) policy

    MassHealth stopped covering drugs for the treatment of obesity or overweight (Wegovy, Zepbound, Saxenda, Xenical, phentermine); approved weight-loss PAs expired July 2. Coverage continues for type 2 diabetes and other approved indications. Brings the covering-state count to 11

    mass.gov

  16. Express Scripts (Evernorth / Cigna) policy

    NPF document lists Foundayo preferred; Zepbound KwikPens and vials excluded

    express-scripts.com

  17. Humana policy

    Medicare GLP-1 Bridge live — Humana is the national central processor

    cms.gov

  18. Medicare (Part D + GLP-1 Bridge) policy

    GLP-1 Bridge live at pharmacies; CMS Parts C & D appeals guidance update effective July 6, 2026

    cms.gov

  19. Optum Rx (UnitedHealthcare) policy

    Weight-loss PA policy updated (P 1114-21): adds Wegovy tablet, MASH pathway

    uhcprovider.com

  20. Medicaid (state-by-state) policy

    Utah's obesity GLP-1 pilot ended; Utah no longer covers GLP-1s for weight management

    therxindex.com

  21. Kaiser Permanente policy

    NW Zepbound criteria re-issued, keeping the 6-month semaglutide-first step

    healthy.kaiserpermanente.org

  22. Express Scripts (Evernorth / Cigna) policy

    Cigna replaced the single weight-loss GLP-1 prior authorization policy with one policy per drug — the criteria did not change, but if you are citing the old combined document in an appeal it now returns a dead link, so quote the policy for your own drug instead

    static.cigna.com

  23. CVS Caremark policy

    Foundayo new-to-market block removed

    cvshealth.com

  24. Elevance Health / Anthem (CarelonRx) policy

    Foundayo added at Tier 2 PA/QL across major lists — fastest add among the majors

    anthembluecross.com

  25. Medicaid (state-by-state) policy

    BALANCE Medicaid rolling participation window opened

    cms.gov

  26. Humana policy

    BALANCE Part D component indefinitely delayed; Bridge extended through Dec 31, 2027

    aha.org

  27. Medicare (Part D + GLP-1 Bridge) policy

    BALANCE Part D component indefinitely delayed; Bridge extended through Dec 31, 2027. CMS now states both in its own words: the BALANCE page answers 'Will the Medicare GLP-1 Bridge continue into 2027?' with 'Yes. The Medicare GLP-1 Bridge has been extended through December 31, 2027', and both that page and the Bridge page carry a question about the impact of 'the BALANCE Model not launching in Medicare in 2027', saying the extension lets CMS collect GLP-1 utilisation data to share with Part D sponsors ahead of potential implementation of BALANCE in Part D

    cms.gov

  28. Discount card at retail (GoodRx and similar) price

    Wegovy® tablets (oral semaglutide) 4 mg moves from $149 to $199/month. ↑ $50/mo

    grxstatic.com

  29. Elevance Health / Anthem (CarelonRx) policy

    Saxenda moved Tier 3 -> non-formulary on the National Drug List and the National Direct, Direct Plus and Direct Preferred lists; generic liraglutide is the covered alternative

    anthembluecross.com

  30. Aetna (CVS Health) policy

    CPB 0039 (Weight Reduction) re-reviewed

    aetna.com

  31. Blue Cross Blue Shield Federal Employee Program (FEP) policy

    Zepbound split into new policy 5.99.031 (two-oral + preferred-product step) and moved to the Standard excluded list; generic liraglutide added Tier 1; FEP cited 'rapid increase in the use of weight loss GLP-1s' as the cost driver

    fepblue.org

  32. Elevance Health / Anthem (CarelonRx) policy

    Anthem CA Medi-Cal terminated weight-loss GLP-1 coverage (Wegovy keeps MASH/CV pathways, Zepbound keeps OSA; Reject Code 70 otherwise)

    providers.anthem.com

  33. Elevance Health / Anthem (CarelonRx) policy

    Generic liraglutide (weight management) moved non-formulary -> Tier 1 on all four California lists, becoming the covered anti-obesity GLP-1 there after Wegovy and Saxenda came off in July 2025

    anthembluecross.com

  34. Express Scripts (Evernorth / Cigna) policy

    2026 NPF year began — 48 new exclusions, GLP-1 anti-obesity class core retained

    psgconsults.com

  35. Express Scripts (Evernorth / Cigna) policy

    Saxenda excluded from the National Preferred Formulary for the 2026 plan year; generic liraglutide is the covered agent

    express-scripts.com

  36. Kaiser Permanente policy

    Medi-Cal carve-out ended weight-loss GLP-1s for KP Medi-Cal members (state action)

    providers.anthem.com

  37. Medicaid (state-by-state) policy

    California kept two doors open after dropping weight-loss GLP-1s from the Medi-Cal Rx contract list: members under 21 can still have a weight-loss request reviewed for medical necessity under the federal EPSDT benefit, and Wegovy for MASH or cardiovascular disease and Zepbound for obstructive sleep apnea remain reviewable by prior authorization for everyone. Otherwise Wegovy, Zepbound and Saxenda deny with Reject Code 70 and existing approvals expired

    providers.anthem.com

  38. Medicaid (state-by-state) policy

    California, New Hampshire, Pennsylvania, South Carolina eliminated obesity GLP-1 coverage; North Carolina dropped Oct 2025 then reinstated Dec 2025

    therxindex.com

  39. Medicaid (state-by-state) policy

    Michigan Medicaid reduced obesity GLP-1 coverage under Public Act 22 of 2025 (FY2026 budget) rather than eliminating it: liraglutide, Saxenda, Wegovy and Zepbound keep their other covered indications unchanged, while a request to treat obesity now needs the patient classified as morbidly obese, documented failure of all other clinically appropriate weight-loss interventions including the preferred anti-obesity agents, and a prescriber attestation that the drug is considered only as a measure to avert the need for higher-cost bariatric surgery. Authorizations approved before Jan 1, 2026 were honored for their remaining six months, and Saxenda and Wegovy became non-preferred on the Single PDL for their other indications, which carries a $3 copayment instead of $1

    michigan.gov

  40. Medicaid (state-by-state) policy

    Pennsylvania Medical Assistance also dropped Saxenda (liraglutide) for EVERY indication, not only for obesity — a withdrawal none of the multi-state trackers carry. Its own bulletin confirms GLP-1s stay covered for all other medically accepted indications with prior authorization, adds a GLP-1 therapeutic class to the Statewide PDL, and keeps non-GLP-1 obesity agents such as phentermine covered, preferred ones without PA

    pa.gov

  41. Medicare (Part D + GLP-1 Bridge) policy

    Part D redetermination window changed 60 -> 65 days; 2026 appeal AIC thresholds $200 / $1,960

    federalregister.gov

  42. Optum Rx (UnitedHealthcare) policy

    2026 Premium formulary exclusions (12 drugs) included no GLP-1 changes

    psgconsults.com

  43. Elevance Health / Anthem (CarelonRx) policy

    Wegovy tablets added non-formulary -> Tier 2 on the national and Essential lists

    anthembluecross.com

  44. Aetna (CVS Health) policy

    Zepbound off standard template; Wegovy sole preferred (CVS reported >95% of members transitioned)

    cvshealth.com

  45. CVS Caremark policy

    Zepbound removed from standard commercial template formularies; switching among 700,907 tracked patients spiked 17x (0.6% to 10.2%/month, June-July)

    managedhealthcareexecutive.com

  46. Elevance Health / Anthem (CarelonRx) policy

    California lists diverged from the national ones: Wegovy Tier 2 -> non-formulary and Zepbound Tier 2 -> Tier 3 on all four (CDI and DMHC, National and Essential)

    anthembluecross.com

  47. Optum Rx (UnitedHealthcare) policy

    UHC added Zepbound OSA pathway (policy P 1475-1)

    psgconsults.com

  48. CVS Caremark policy

    Announced Wegovy as preferred GLP-1 for obesity

    prnewswire.com

  49. Kaiser Permanente policy

    CA base commercial plans removed Wegovy for BMI < 40

    findhonestcare.com

Every row here is a dated entry in the corpus with its own source link. Where a payer publishes a change but not its full criteria, the plan page carries a confidence grade saying so — we would rather show you a gap than fill it with a guess.